Table 2.

Studies examining various interventions for age-related muscle loss

Study	Population	Gender	Age	N	Intervention	Findings
Solerte et al. (2008) [149]	S	M, F	66–84	41	AA supp.	↑Lean mass, ↑IGF-1, ↓TNF-α
Trappe et al. (2000) [150]	E	M	74 ± 2	7	RT	↑S; ↑MHC I
Trappe et al. (2001) [151]	E	F	74 ± 2	7	RT	↑S
Slivka et al. (2008) [152]	E	M	80–86	6	RT	↑S, ↑CSA
Fiatarone et al. (1990) [93]	E	M	90 ± 3	10	HIRT	↑S, ↑CSA
Kryger et al. (2007) [153]	E	M, F	85–97	11	RT	↑S, ↑CSA
Frontera et al. (2003) [154]	E	F	68–79	14	RT	↑S, ↑CSA
Wittert et al. (2003) [155]	E	M	60–86	76	TE	↔S, ↑CSA

S sarcopenia, E elderly, Myo-29 a myostatin inhibiting drug, AA Supp amino acid supplement, RT resistance training, HIRT high-intensity resistance training, TE testosterone, S strength, CSA muscle cross-sectional area, IGF-1 insulin-like growth factor 1, TNF-α tumor necrosis factor alpha, MHC I, myosin heavy chain type I isoform